亚宝药业(600351) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥677,823,380.81, representing a year-on-year increase of 1.68%[2] - The net profit attributable to shareholders for Q3 2024 was ¥55,158,750.33, an increase of 20.46% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥54,617,047.44, up 47.46% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0769, an increase of 26.08% compared to the same period last year[7] - The net profit attributable to shareholders for the year-to-date period was ¥234,933,135.46, reflecting a year-on-year increase of 9.88%[2] - Net profit for the first three quarters of 2024 was CNY 228,467,854.51, an increase of 7.92% compared to CNY 212,501,544.38 in 2023[14] - The net profit for the first three quarters of 2024 was ¥368,826,642.18, compared to ¥207,509,546.34 in the same period of 2023, reflecting a growth of 77.5%[22] Cash Flow - The net cash flow from operating activities for Q3 2024 decreased by 49.52%, amounting to ¥40,279,799.41[6] - In the first three quarters of 2024, the net cash flow from operating activities was RMB 382,420,349.68, an increase from RMB 334,535,144.89 in the same period of 2023, reflecting a growth of approximately 14.5%[17] - Total cash inflow from operating activities decreased to RMB 1,899,547,705.51 in 2024 from RMB 2,145,487,915.72 in 2023, representing a decline of about 11.5%[17] - The total cash outflow from operating activities was RMB 1,517,127,355.83, down from RMB 1,810,952,770.83 in 2023, indicating a reduction of approximately 16.2%[17] - Cash inflow from operating activities for the first nine months was CNY 927.14 million, a decrease of 6.6% compared to CNY 992.56 million in the same period last year[23] - Total cash outflow for operating activities was CNY 586.88 million, a decrease of 14.5% from CNY 686.76 million last year[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,693,235,028.7, a decrease of 4.16% from the end of the previous year[3] - As of September 30, 2024, total current assets amounted to approximately CNY 1.66 billion, a decrease from CNY 1.75 billion as of December 31, 2023, reflecting a decline of about 5.1%[10] - Total non-current assets decreased to approximately CNY 2.04 billion from CNY 2.10 billion, a decline of about 3.3%[11] - The total liabilities decreased to CNY 708,410,928.29 from CNY 860,330,813.75, a reduction of 17.63%[14] - The total equity attributable to shareholders was CNY 2,952,235,544.54, slightly down from CNY 2,976,188,510.38 in 2023[14] - The total assets as of the end of the third quarter were ¥3,768,118,876.69, down from ¥3,918,761,668.94 at the end of the previous year[20] - The total liabilities decreased to ¥553,467,628.16 from ¥793,259,937.01 year-over-year[20] Research and Development - The company continues to focus on research and development, with development expenditures reported at approximately CNY 152.24 million, up from CNY 150.81 million[11] - Research and development expenses increased to CNY 89,911,769.62, compared to CNY 84,570,401.25 in the previous year, reflecting a growth of 6.67%[13] - Research and development expenses for the first three quarters of 2024 were ¥58,920,327.32, slightly lower than ¥60,545,419.43 in the same period of 2023[21] Shareholder Information - The largest shareholder, Shanxi Yabao Investment Group, holds 13.10% of the shares, totaling 94.30 million shares[9] - The company has not reported any changes in the top ten shareholders or their shareholding status due to margin trading activities[10] Government Subsidies - The company reported a government subsidy of ¥4,645,809.49 for the current period, contributing to its non-recurring gains[4] Inventory and Receivables - Accounts receivable increased to CNY 440.53 million from CNY 346.81 million, representing a growth of approximately 27%[10] - Inventory decreased to CNY 354.90 million from CNY 442.13 million, indicating a reduction of about 19.7%[10] - The company's inventory decreased to RMB 216,313,808.54 as of September 30, 2024, down from RMB 260,254,233.80 at the end of 2023, reflecting a reduction of approximately 17%[18] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[22]